CARsgen Therapeutics IPO: Valuation Insights
Due to the full IPO price range, lack of blue-chip cornerstone support and the current weak market sentiment on IPOs, we are inclined to wait on...
598 Views
ECM Weekly (30th May 2021) - JD Log, Monde Nissin, Weilong Deli, Kanzhun, CARsgen, WM Tech, Novotech
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.
508 Views
CARSgen Therapeutics IPO: Catalyzing Cancer Therapies
CARSgen’s core product CT053 shows significant potential given its positive ORR and receiving the US FDA RMAT designation.
575 Views
CARsgen Therapeutics IPO Initiation: Choosing Therapies À La CAR-T
CARsgen is pre-marketing an HKEx IPO to raise proceeds of $400-500m. The promising prospects for the lead product, credible management and a good...
489 Views
CARsgen (科济药业) Pre-IPO: Thoughts on Valuation
In this insight, we provide a risk-adjusted NPV based valuation for the company's key product CT035 and the SOTP valuation for the company.
605 Views